It was originally dropped as a treatment for high cholesterol by Bristol-Myers Squibb because of the liver toxicity issues, but a University of Pennsylvania cardiologist, Daniel Rader, championed the drug, leading Aegerion to develop it.
On the day Lib Dem high flyer David Laws was clobbered over his expenses, no MP should be in any doubt about the lingering toxicity of this issue for parliamentarians.